Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DICE Therapeutics, Inc. - Common Stock (NQ: DICE )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DICE Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
DICE Announces Proposed Public Offering of Common Stock
From DICE Therapeutics, Inc.
Via GlobeNewswire
Nasdaq Drops 150 Points; AZZ Shares Plummet
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 150 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
Dow Surges Over 100 Points; Crude Oil Down 2%
U.S. stocks pared some losses midway through trading, with the Dow Jones gaining more than 100 points on Tuesday. 
Via Benzinga
What Is Going on With DICE Therapeutics (DICE) Stock?
Shares of DICE stock are up an astounding 50% today on news of a positive clinical trial related to the Dice's psoriasis treatment. 
Via InvestorPlace
DICE Therapeutics Stock Doubles After Positive Data From Lead Psoriasis Candidate
Via Benzinga
HC Wainwright Is Bullish On DICE Therapeutics - Read Why
Via Benzinga
Why ForgeRock Shares Are Trading Higher By Over 49%, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
Gainers FedNat Holding Company (NASDAQ: FNHC) shares jumped 140% to $0.3939. 
Via Benzinga
DICE Therapeutics, Amgen And Some Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded mostly lower, with the Nasdaq dropping more than 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
US Stocks Open Lower, Dow Falls 100 Points
U.S. stocks traded lower this morning, with the Dow Jones dropping around 100 points on Tuesday. 
Via Benzinga
Analyzing DICE Therapeutics's Short Interest
DICE Therapeutics's (NASDAQ:DICE) short percent of float has fallen 5.55% since its last report. The company recently reported that it has 4.93 million shares sold short, which is 17.52% of all regular... 
Via Benzinga
Nasdaq Bear Market: 2 Stocks Defying the Downturn
One of these companies is a leader in its niche, while the other wants to become one. 
Via The Motley Fool
Dice Therapeutics Surges To Record High As Psoriasis Pill Promises To Lead Its Class
The company is testing a potential pill to treat psoriasis. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers DICE Therapeutics (NASDAQ:DICE) stock moved upwards by 83.4% to $45.2 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.7 billion. 
Via Benzinga
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis
From DICE Therapeutics, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Looking Into DICE Therapeutics's Recent Short Interest
DICE Therapeutics's (NASDAQ:DICE) short percent of float has fallen 7.8% since its last report. The company recently reported that it has 5.22 million shares sold short, which... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low... 
Via Benzinga
Dow Up Over 280 Points, Fourth-Straight Win In Sight
Stocks are firmly higher midday, with the Dow Jones Industrial Average last seen up over 280 points, while both the S&P 500 Index and Nasdaq Composite boast sizable gains of their own. 
Via Talk Markets
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split. 
Via Benzinga
Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session
Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65. 
Via Benzinga
Livent, Amgen And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
US Stocks Open Higher, Nasdaq Surges Over 100 Points
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Biofrontera (NASDAQ:BFRI) shares ... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Pasithea Therapeutics (NASDAQ:KTTA 
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Xiaobai Maimai Inc. (NASDAQ: HX) shares surged 98.4% to settle at $18.87 on Wednesday on above-average volume. The company on Tuesday disclosed the resignation of its CEO... 
Via Benzinga
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2021
Upgrades According to Vertical Research, the prior rating for C.H. Robinson Worldwide Inc (NASDAQ: 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.